Group 1 - The core focus events for Dize Pharmaceutical in 2026 and beyond include the progress of H-share listing, key milestones in the R&D pipeline, annual business plan review, and commercialization and market expansion [1] - Dize Pharmaceutical submitted its H-share listing application to the Hong Kong Stock Exchange on January 23, 2026, aiming for a dual listing in Hong Kong to enhance its global strategy and attract international investors [2] - The company plans to advance multiple core products into clinical data update stages in 2026, including the global multi-center Phase III study of Shuwotai (Shuwotai) for EGFR Exon20ins non-small cell lung cancer, which has completed patient enrollment [3] Group 2 - Dize Pharmaceutical plans to hold a board meeting in 2026 to review the annual sales plan, which is yet to be finalized and will be disclosed after board approval [4] - The company aims to leverage the inclusion of core products Shuwotai and Guaizhe in the national medical insurance catalog to deepen domestic market coverage and promote overseas commercialization in 2026 [5] - The sales expense ratio decreased to 72% in the first three quarters of 2025, and the company plans to further enhance operational efficiency in 2026 [5]

Core Viewpoint - DIZHE Pharmaceutical (688192.SH) is pursuing an "A+H" listing by submitting an application to the Hong Kong Stock Exchange, aiming to raise funds for clinical development, sales, and operational expenses, while currently being in the commercialization phase with two approved products [2][3]. Financial Performance - The company raised approximately 2.1 billion yuan in its 2021 IPO and 1.8 billion yuan through a private placement in April 2025 [2]. - DIZHE expects to achieve revenue of around 800 million yuan in 2025, representing a year-on-year growth of approximately 122.28%, with a projected net loss of about 770 million yuan [2][5]. - The company reported a net profit of approximately -1.1 billion yuan in 2023 and -846 million yuan in 2024, with an expected reduction in net loss by about 75.96 million yuan in 2025 [7]. Product Pipeline and Market Strategy - DIZHE has two approved products, Shuwotini (舒沃哲) and Gelixitini (高瑞哲), which are expected to significantly enhance patient accessibility after being included in the national medical insurance catalog [4][5]. - The company is focusing on expanding the indications for its existing products and advancing its pipeline, which includes seven products currently in clinical stages [8]. R&D Investment and Challenges - DIZHE is in the early stages of commercialization and continues to incur significant R&D expenses, with an expected R&D expenditure of around 860 million yuan in 2025, reflecting a year-on-year increase of approximately 18.84% [7]. - The company is facing challenges in achieving positive operating cash flow, as it continues to invest heavily in R&D while striving for commercial profitability [6][8]. Market Position and Future Outlook - DIZHE aims to leverage its products' inclusion in the medical insurance directory to enhance market penetration and drive revenue growth, with a sales expense ratio significantly reduced to 72% in the first three quarters of 2025 [6]. - The company is committed to ensuring the advancement of its core global pipeline and key market development while maintaining a focus on sustainable high-quality profitability [8][9].

Core Insights - The A-share biopharmaceutical companies are expected to deliver innovative results in 2025, benefiting from industry recovery, overseas market expansion, and favorable pharmaceutical policies [2] - Over 90 A-share biopharmaceutical companies have released performance forecasts for 2025, with 53 companies expected to be profitable [2] - Among the profit forecasts, 14 companies anticipate a net profit increase of over 100%, while 10 companies expect to turn losses into profits [3][2] Group 1: Performance Growth Drivers - Sales volume growth and internal cost reduction are key factors for the significant profit increases among the companies [4] - Shanghai Yizhong leads with a projected net profit increase of 760.18% to 903.54%, expecting a net profit of 60 million to 70 million yuan in 2025 due to its core product being included in the national medical insurance directory [4] - Yuheng Pharmaceutical anticipates a net profit of 350 million to 420 million yuan, a year-on-year increase of 50.37% to 80.44%, driven by steady sales growth of its products [4] - Nawei Technology expects a net profit of 128 million to 145 million yuan, a year-on-year increase of 54.51% to 75.03%, focusing on market strategies in key sectors [4][5] Group 2: International Market Expansion - International business is a significant growth driver for biopharmaceutical companies [6] - WuXi AppTec, a leading CXO company, forecasts a revenue of 45.456 billion yuan, a year-on-year increase of approximately 15.84%, and a net profit of 19.151 billion yuan, a 102.65% increase [6] - Ganli Pharmaceutical expects a net profit of 1.1 billion to 1.2 billion yuan, a year-on-year increase of 78.96% to 95.23%, attributed to steady growth in domestic and international revenues [6] Group 3: Innovation and Recovery - Several innovative drug companies are entering a recovery phase, with many turning losses into profits or significantly reducing losses [8] - BeiGene expects a full-year operating profit for 2025, with revenue projections between 36.2 billion and 38.1 billion yuan, reflecting an upward adjustment from previous estimates [8] - DiZhe Pharmaceutical anticipates a revenue of 800 million yuan, a year-on-year increase of 122.28%, with a reduced net loss of 770 million yuan [9]

Company Overview - Dize Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, with Goldman Sachs and Huatai International as joint sponsors [1] - The company is a commercial-stage biopharmaceutical firm focusing on oncology and hematological diseases [1] Core Products - The core drug, Shuwozhe, is the only approved small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for treating EGFR 20 insertion mutation lung cancer globally [1] - Shuwozhe is the first lung cancer drug developed in China to receive breakthrough therapy designation from both the FDA and the National Medical Products Administration of China [1] - It is the only targeted drug recommended by the NCCN guidelines for non-small cell lung cancer (NSCLC) and included in China's national medical insurance catalog for this indication as of January 18, 2026 [1] - The second core drug, Gaoruizhe, is the first and only approved JAK1 inhibitor for treating relapsed or refractory peripheral T-cell lymphoma [1] - Gaoruizhe has received fast track and orphan drug designations from the FDA and is also included in China's national medical insurance catalog [1] Pipeline and Market Potential - In addition to the two approved drugs, the pipeline includes one asset in the registration clinical stage, three in the post-concept validation stage, and one in the early clinical stage [1] - The global and Chinese oncology drug markets are experiencing significant growth, particularly in the treatment of lung cancer and NSCLC, which have substantial unmet medical needs [1] - The global market for EGFR 20 insertion mutation NSCLC is projected to grow from $1 billion in 2024 to $8 billion by 2035 [1]

Core Viewpoint - Dize Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, focusing on its innovative cancer treatment products, particularly Shuwozhe and GaoRuizhe, which are pivotal for the company's revenue generation [1][2]. Group 1: Company Overview - Dize Pharmaceutical is a commercial-stage biopharmaceutical company specializing in oncology and hematological diseases [1]. - The company’s main product, Shuwozhe, is the only approved small molecule EGFR tyrosine kinase inhibitor for treating EGFR 20 insertion mutation lung cancer globally [1]. - GaoRuizhe is the first and only JAK1 inhibitor approved for treating relapsed or refractory peripheral T-cell lymphoma [2]. Group 2: Financial Performance - Revenue for Dize Pharmaceutical during the reporting period (2023, 2024, and the first three quarters of 2025) was RMB 91.29 million, RMB 360 million, and RMB 586 million respectively [2][3]. - Shuwozhe's revenue contribution was 100%, 86.4%, and 72% over the same periods, indicating a decline in its revenue share but still being the primary income source [2]. - The company reported net losses of RMB 1.11 billion, RMB 940 million, and RMB 649 million for the respective years [2][3]. Group 3: Cost Structure and Profitability - The company has incurred significant R&D expenses, amounting to RMB 806 million, RMB 724 million, and RMB 644 million, which are substantially higher than its revenue [4]. - Gross profit margins were relatively high at 96.5%, 97.4%, and 95.7%, attributed to strong R&D capabilities and pricing power from innovative products [4]. - The company has faced continuous net losses since its establishment, accumulating over RMB 4 billion in losses from 2018 to 2024 [3][4]. Group 4: Market Position and Client Concentration - Dize Pharmaceutical's revenue is highly concentrated, with the top five customers accounting for 90.8%, 89.6%, and 81.7% of total revenue during the reporting periods, and the largest customer contributing around 40% [5]. - The company also relies on a limited number of suppliers, with the top five suppliers representing 60.6%, 57.0%, and 57.8% of total procurement [5]. - Dize Pharmaceutical was founded in October 2017 and was listed on the Shanghai Stock Exchange in December 2021, with a current market capitalization of RMB 27.84 billion [5].

Trading Information - On January 12, 2026, Dize Pharmaceutical (688192) closed at 66.94 yuan, with a slight increase of 0.22% and a turnover rate of 0.76%. The trading volume was 34,500 shares, with a total transaction value of 231 million yuan [1] - On the same day, the net inflow of main funds was 4.5775 million yuan, accounting for 1.98% of the total transaction value. The net inflow of speculative funds was 7.0625 million yuan, accounting for 3.05% of the total transaction value. Retail investors had a net outflow of 11.6399 million yuan, accounting for 5.03% of the total transaction value [1][4] Performance Forecast - Dize Pharmaceutical has released a performance forecast, estimating a total revenue of approximately 800 million yuan for the year 2025. The company anticipates a net loss of about 850 million yuan after deducting non-recurring items and a net loss attributable to shareholders of approximately 770 million yuan [2][4] Company Announcements - Dize Pharmaceutical expects to achieve an annual revenue of around 800 million yuan in 2025, representing a year-on-year increase of 122.28%. The R&D expenses are projected to be around 860 million yuan, reflecting an 18.84% year-on-year increase. The net loss attributable to the parent company is estimated to be around 770 million yuan, which is a reduction in loss of 8.98% year-on-year. The losses are primarily due to sustained high R&D investments [3] - Two products, Shuwozhe and Gaoruizhe, have been included in the national medical insurance catalog. Additionally, Shuwozhe has received FDA approval and has been included in the NCCN guidelines. The company has also reported multiple clinical progress updates for its pipeline products and has received FDA fast track designation [3][4]

Core Viewpoint - Dize Pharmaceutical (688192.SH) forecasts a net loss of approximately 770 million yuan for the fiscal year 2025, which represents a reduction in losses of about 75.96 million yuan compared to the same period last year [1] Group 1 - The company expects its sales revenue to reach around 800 million yuan, marking a year-on-year increase of 122.28% [1] - Two approved products, Shuwozhe and Gaoruizhe, have been included in the national medical insurance drug list, contributing to the sales growth [1]

Core Insights - The article discusses significant developments in the pharmaceutical and healthcare industry, including leadership changes, regulatory approvals, and strategic collaborations aimed at enhancing treatment options for patients with complex conditions like brain metastases [14][4][12]. Policy Developments - The National Medical Products Administration (NMPA) is focusing on balancing safety and development, emphasizing the importance of legal administration and scientific regulation to protect the legitimate rights of enterprises and promote high-quality industry development [2]. Drug Approvals - Yuandong Biotech received a drug registration certificate for Brivaracetam tablets, marking it as the first generic drug approved under the new registration classification in China. The expected sales for the original drug are approximately 160,000 yuan in the first half of 2025 [4]. - Jiutian Pharmaceutical has received approval for clinical trials of JMHT06 for treating acute gouty arthritis [5]. Capital Market Activities - L'Oréal plans to increase its stake in Galderma by acquiring an additional 10% of shares, which will raise its total ownership to 20% by early 2026. This move includes the nomination of two non-independent directors from L'Oréal to Galderma's board [7]. Industry Collaborations - Baiyang Pharmaceutical is collaborating with multiple medical institutions to enhance treatment for brain metastases, including launching real-world studies with ZAP-X technology and establishing a precision radiotherapy center [12][9].

Group 1 - The core viewpoint of the article highlights that innovative pharmaceutical companies are transitioning from a "research and development investment phase" to a "commercialization harvest phase," driven by policy benefits, capital support, and clinical demand [1][4][5] Group 2 - Innovative pharmaceutical companies have reported impressive third-quarter results, with BeiGene achieving over 10 billion yuan in revenue, a year-on-year increase of 41.1%, and total revenue for the first three quarters reaching 27.595 billion yuan, up 44.2% [2] - Other leading innovative pharmaceutical companies also showed strong performance, with Hengrui Medicine reporting a revenue of 23.188 billion yuan for the first three quarters, a year-on-year growth of 14.85%, and WuXi AppTec achieving 32.857 billion yuan in revenue, up 18.61% [3] - The sales growth of core products, such as BeiGene's Zebrutinib and Junshi Biosciences' Toripalimab, is driving the performance of these companies, indicating a significant return on investment in research and development [5][6] Group 3 - The innovative drug sector is experiencing rapid growth, with a notable increase in business development (BD) transactions, totaling 92.03 billion USD in the first three quarters of 2025, reflecting a surge in licensing deals for domestic innovative drugs [6] - Analysts from Dongwu Securities express optimism about the innovative drug sector, predicting it will remain a key investment theme in the pharmaceutical industry through 2026, driven by the rising international status of Chinese innovative drug companies and a boom in BD transactions [7]

Core Viewpoint - The Chinese innovative drug market is entering a rapid development phase, with local leading companies like Heng Rui benefiting from policy support and industry expansion opportunities [1] Company Performance - Heng Rui Pharmaceutical reported a revenue of 23.188 billion yuan for the first three quarters of 2025, a year-on-year increase of 14.85%, and a net profit of 5.751 billion yuan, up 24.50% [2] - The company has received a total cash dividend of over 9.3 billion yuan, enhancing investor returns [1] - The company has established a differentiated competitive advantage through over 50 billion yuan in R&D investment and has 24 innovative drugs approved for sale in China [1] Industry Trends - The innovative drug sector is experiencing accelerated commercialization and increased business development (BD) transactions, leading to a sustained trend of rapid growth in performance [1] - Other innovative drug companies, such as Zai Lab and DiZhe Pharmaceutical, are also reporting significant revenue growth, with Zai Lab achieving a 54.49% increase in revenue to 593 million yuan [3] - The industry is expected to continue its growth trajectory, supported by favorable national policies and increasing international collaboration [4][5] R&D Focus - Heng Rui's innovative drugs, including Rivoceranib and Darsylis, are addressing unmet clinical needs, contributing to their revenue growth [2] - Zai Lab emphasizes its differentiated product pipeline focusing on oncology and autoimmune diseases, aiming to fill domestic gaps in treatment options [3] - The industry is witnessing a rise in R&D investments, with companies like Yi Fang Bio reporting a total R&D investment of 190 million yuan for the first three quarters of 2025 [4] Future Outlook - Analysts predict a new round of growth for the pharmaceutical sector, particularly in innovative drugs, as the international standing of Chinese innovative drug companies rises [5] - The innovative drug sector is expected to remain a key investment theme in the pharmaceutical industry through 2026, driven by increased BD transactions and international collaborations [5]